Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Legal / IP Policy / Regulatory

China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Drug

Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential

Fineline Cube May 8, 2026
Company Drug

Novatim Immune Therapeutics’ Y-0301 Receives FDA Clearance for Clinical Trials

Fineline Cube Dec 7, 2024

China-based cancer immunotherapy specialist Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has announced receiving clinical clearance...

Policy / Regulatory

NMPA Releases 85th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Dec 7, 2024

The National Medical Products Administration (NMPA) has released the 85th batch of reference drugs for...

Company Drug

HighField Biopharmaceutical’s HF50 Receives Tacit Clinical Approval from NMPA for HER-2 Positive Tumors

Fineline Cube Dec 7, 2024

Hangzhou-based HighField Biopharmaceutical, a specialist in immuno-oncology biotech focused on targeted lipid-based therapies, has revealed...

Company Drug

Shenyang Hongqi Pharma Secures NMPA Approval for Pretomanid in TB Treatment

Fineline Cube Dec 6, 2024

The National Medical Products Administration (NMPA) of China has officially approved pretomanid, developed by Shenyang...

Company Deals

Chongqing Zhifei Biological and GlaxoSmithKline Amend Distribution Agreement for Herpes Vaccine

Fineline Cube Dec 6, 2024

China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a supplementary exclusive distribution...

Company Deals

GSK plc Partners with Muna Therapeutics to Discover Alzheimer’s Disease Treatment Targets

Fineline Cube Dec 6, 2024

GSK plc (NYSE: GSK) has announced a new partnership with Danish biotech firm Muna Therapeutics,...

Company Drug

Jiangsu Hengrui’s SHR-A2102 Earns Breakthrough Therapy Designation for Urothelial Carcinoma

Fineline Cube Dec 6, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received breakthrough therapy...

Company Drug

Roche’s Columvi Supplemental sBLA Accepted by FDA for Relapsed DLBCL Treatment

Fineline Cube Dec 6, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the US Food and Drug Administration...

Company Drug

Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI

Fineline Cube Dec 6, 2024

Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced its intention to sell all holdings...

Company Deals

Eyebright Medical Technology Aims to Raise RMB 300 Million for Contact Lens Production Expansion

Fineline Cube Dec 6, 2024

China-based ophthalmic medical device manufacturer, Eyebright Medical Technology Co., Ltd (SHA: 688050), has announced plans...

Company Deals

Cambrex Partners with Eli Lilly to Enhance Clinical Development for Biotech Collaborators

Fineline Cube Dec 6, 2024

US-based contract development and manufacturing organization (CDMO) Cambrex has reached an agreement with Eli Lilly...

Company Deals Drug

Dewpoint Therapeutics Partners with Mitsubishi Tanabe Pharma to Develop ALS Treatment

Fineline Cube Dec 6, 2024

US-based Dewpoint Therapeutics Inc. has entered into a strategic partnership with Japan-headquartered Mitsubishi Tanabe Pharma...

Company Drug

AstraZeneca’s Imfinzi Receives FDA Approval for Limited-Stage Small Cell Lung Cancer

Fineline Cube Dec 6, 2024

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has reported receiving a new indication approval from...

Company

Eli Lilly & Co. Expands Wisconsin Manufacturing Facility with $3 Billion Investment

Fineline Cube Dec 6, 2024

US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the expansion of its...

Company

Amgen Expands Biomanufacturing Footprint in North Carolina with Second Facility

Fineline Cube Dec 6, 2024

US biotech company Amgen (NASDAQ: AMGN) has announced plans to construct a second drug substance...

Company Drug

Merck Initiates Phase III MOVE-NOW Study for Lagevrio COVID-19 Antiviral

Fineline Cube Dec 6, 2024

US pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced the commencement of the...

Company Drug

CDE Approves RinuaGene’s mRNA-Based RG002 for Clinical Study in Cervical Dysplasia

Fineline Cube Dec 6, 2024

China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has indicated...

Company

Burning Rock Ltd Reports Q3 2024 Financials with Revenue Growth and R&D Reduction

Fineline Cube Dec 5, 2024

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has released its financial results for the...

Company Deals

Novavax to Sell Czech Manufacturing Facility to Novo Nordisk for $200 Million

Fineline Cube Dec 5, 2024

US-based Novavax, Inc. (NASDAQ: NVAX) has reached an agreement to sell its manufacturing facility located...

Hospital Policy / Regulatory

China’s Health Commission Issues Guidelines to Strengthen Ties Between Healthcare and Elderly Care

Fineline Cube Dec 5, 2024

The National Health Commission, in conjunction with three other bureaus, has issued the “Notice on...

Posts pagination

1 … 247 248 249 … 661

Recent updates

  • Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment
  • Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential
  • Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy
  • Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment
  • China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Company Drug

Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential

Company Drug

Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy

Company Drug

Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.